Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT00730847 Terminated - Clinical trials for Human Papillomavirus Infection Leading to Cervical Cancer

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Start date: September 17, 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the safety and reactogenicity of GSK Biologicals' Cervarix vaccine in healthy female Filipino subjects from the age of 10 years onwards, as per the Bureau of Food and Drugs Directive of Philippines.

NCT ID: NCT00730574 Terminated - Clinical trials for B12 Deficiency Combined With C677T Mutation on MTHFR Gene

Examining B12 Deficiency Associated With C677T Mutation on MTHFR Gene in Terms of Commonness and Endothelial Function

Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the commonness of the C677T mutation in the MTHFR gene in subjects with B12 deficiency. Also, we'd like to investigate the effect of B12 deficiency combined with the C677T mutation on endothelial function.

NCT ID: NCT00728429 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

Start date: June 2008
Phase: N/A
Study type: Interventional

RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works in patients receiving chemotherapy for cancer.

NCT ID: NCT00727532 Terminated - Kidney Cancer Clinical Trials

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Start date: July 2008
Phase: N/A
Study type: Interventional

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with locally advanced or metastatic kidney cancer.

NCT ID: NCT00726830 Terminated - Pain Clinical Trials

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Start date: March 2009
Phase: N/A
Study type: Interventional

RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer.

NCT ID: NCT00726570 Terminated - Clinical trials for Postoperative Complications

Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs

TEGLeg
Start date: August 2008
Phase: N/A
Study type: Interventional

This study aims to assess possible alteration in coagulation (blood clotting) following treatment with sequential compression devices (SCD) plus low-molecular weight heparin (LMWH) as opposed to LMWH alone. The investigators will examine coagulation in the early postoperative period of patients undergoing major abdominal surgery during their stay in our Intensive Care Unit. In addition to common laboratory tests, the investigators will examine coagulation using TEG®, a device which allows a semi-quantitative examination of all phases of coagulation.

NCT ID: NCT00726544 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.

NCT ID: NCT00726232 Terminated - Clinical trials for Myeloproliferative Neoplasm (MPN)

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Start date: August 20, 2008
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy profile of different treatment regimens of Ruxolitinib (INCB018424) administered to two groups of patients; those with polycythemia vera (PV) and those with essential thrombocythemia (ET). Patients in each group were refractory to hydroxyurea or for whom hydroxyurea is contraindicated.

NCT ID: NCT00725062 Terminated - Lymphoma Clinical Trials

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Start date: June 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. Giving an infusion of donor T cells may helps stop the patient's immune system from rejecting the donor's stem cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of donor T cells in treating patients with high-risk hematologic cancer who are undergoing donor peripheral blood stem cell transplant. Note: Only Phase I portion of study was performed. Due to slow accrual, study was closed before Phase II portion of study.

NCT ID: NCT00719914 Terminated - Clinical trials for ST-Elevation Myocardial Infarction

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

IC TITAN
Start date: November 2007
Phase: Phase 2
Study type: Interventional

The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly after arriving. This drug is usually given through a vein in the arm. However, eptifibatide can also be injected directly into the heart's blood supply just before angioplasty, a common procedure to unblock a blood vessel in the heart. This new way of giving the drug is being studying.